Furthermore, treatment targeting neuronal C/EBPβ signaling, assisted by an anti-inflammatory agent or oral BDNF mimetic compound such as 7,8-DHF, may ameliorate the onset and progression of both depression and diabetes in the general population. Here, CEBPB is linked to depressive symptom measurement.